CONSTRUCTION OF NEW COMMERCIAL SCALE MANUFACTURING FACILITY

Peplin Limited (ASX:PEP) announced today that it had commenced the construction of a new commercial scale manufacturing facility for the production of GMP (Good Manufacturing Practice) grade PEP005, its lead investigational agent being developed to treat skin cancer and leukemia. The new facility will consolidate under a single roof Peplin's current validated extraction and GMP purification technologies which Peplin has previously operated in two separate facilities. In addition Peplin will implement selected process improvements to optimise productivity.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/a1671209830887c42b546cdfcda77650.html)